Monday, January 23, 2012 9:16:36 AM
"I am excited to have been not only interviewed by the Boston Business Journal, but to be shown in such a high-profile position heading into the weekend. This really showcases the attention that we are starting to receive as the clinical trials for our anti-cancer breakthrough drug Kevetrin™ are nearing," said Leo Ehrlich. "Reflecting upon where we were just one year ago, the progression at Cellceutix has been amazing. We're ready to enter clinical trials at the most prestigious cancer institute in the world. Our pre-clinical research has produced the type of astounding data that, if confirmed in human trials, can change the landscape of cancer therapies. We are now regularly engaged by major publications and large pharmaceutical companies wanting to know more about us and our compounds. These developments are being echoed in the attention to our stock. We were only trading about 1,000 shares a week at this time in 2011, but now trading has increased about 30-fold on an average week and our share price has appreciated by more than 150 percent. I still feel very strongly that this is only the beginning and once we start clinical trials with both Kevetrin and KM-133, the attention is going to increase exponentially. I have listened to comparisons of Cellceutix to billion-dollar pharmas and will remain relentless in my efforts to bring those associations to fruition for the benefit of shareholders of Cellceutix."
Recent NNVC News
- Form 8-K - Current report • Edgar (US Regulatory) • 08/09/2024 08:30:39 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 08/09/2024 08:05:25 PM
- NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • InvestorsHub NewsWire • 05/02/2024 02:07:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
Reliant Coffee Debuts at #271 on the Inc. 5000 List of Fastest Growing Companies - Coffee Service Industry Disruptor Brews Up Exponential Growth Sep 5, 2024 11:51 AM
VAYK Confirms Receiving Revenue from First Airbnb Property with 1.4 Million Annual Revenue Goal • VAYK • Sep 4, 2024 9:34 AM
Mawson Finland Limited Expands Known Mineralized Zones at Rajapalot: New Lens Intercepts 21.75 m at 5.25 g/t Gold & 515 ppm Cobalt • MFL • Sep 4, 2024 9:02 AM
Integrated Ventures Acquires 51% Stake In GetTrim.Com (TM), Telemedicine Platform With Focus On Expansion Into Booming GLP-1 Powered Weight Loss Market • INTV • Sep 4, 2024 8:45 AM
Avant Technologies Announces Strategic Review Process Intended to Maximize Shareholder Value • AVAI • Sep 4, 2024 8:00 AM
PickleJar Launches National "Get on the Bus" Campaign, Unveils Thompson Square Tour Bus Wrap • PKLE • Sep 4, 2024 7:17 AM